(Q57140329)

1

0 references

Reinhard Ziebermayr

2

0 references

Christoph C Zielinski

3

0 references

Guenther G Steger

Wiener Medizinische Wochenschrift

4

0 references

language of work or name

English

0 references

publication date

April 2010

0 references

published in

0 references

volume

160

0 references

issue

7-8

0 references

page(s)

174-81

0 references

exact match

https://scigraph.springernature.com/pub.10.1007/s10354-010-0773-6

0 references

cites work

Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10354-010-0773-6

BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10354-010-0773-6

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

21 January 2018

1 reference

12 December 2020

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

1 reference

12 December 2020

Hallmarks of 'BRCAness' in sporadic cancers

1 reference

12 December 2020

Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer.

1 reference

12 December 2020

Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy

1 reference

12 December 2020

Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer

1 reference

12 December 2020

Bevacizumab for salvage treatment of metastatic breast cancer: a systemic review and meta-analysis of randomized controlled trials

1 reference

12 December 2020

Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma

1 reference

12 December 2020

Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach

1 reference

12 December 2020

Platinum-based chemotherapy in triple-negative breast cancer.

1 reference

12 December 2020

Molecular portraits of human breast tumours

1 reference

12 December 2020

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

1 reference

12 December 2020

EGFR associated expression profiles vary with breast tumor subtype

1 reference

12 December 2020

Repeated observation of breast tumor subtypes in independent gene expression data sets

1 reference

12 December 2020

BRCA1 mutations in primary breast and ovarian carcinomas

1 reference

12 December 2020

Concordance among gene-expression-based predictors for breast cancer

1 reference

12 December 2020

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

1 reference

12 December 2020

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

1 reference

12 December 2020

Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336.

1 reference

12 December 2020

Are triple-negative tumours and basal-like breast cancer synonymous?

1 reference

12 December 2020

Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis

1 reference

12 December 2020

Use of immunohistochemical markers can refine prognosis in triple negative breast cancer

1 reference

12 December 2020

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

12 December 2020

Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells

1 reference

12 December 2020

Third consensus on medical treatment of metastatic breast cancer.

1 reference

12 December 2020

Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database

1 reference

12 December 2020

Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes

1 reference

12 December 2020

Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients

1 reference

12 December 2020

Epidemiology of basal-like breast cancer

1 reference

12 December 2020

Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs

1 reference

12 December 2020

Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy.

1 reference

12 December 2020

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

1 reference

12 December 2020

BRCA1 dysfunction in sporadic basal-like breast cancer

1 reference

12 December 2020

RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic br

1 reference

12 December 2020

The role of BRCA1 in transcriptional regulation and cell cycle control

1 reference

12 December 2020

Triple-negative breast cancer: clinical features and patterns of recurrence

1 reference

12 December 2020

Pathologic Complete Response With Six Compared With Three Cycles of Neoadjuvant Epirubicin Plus Docetaxel and Granulocyte Colony-Stimulating Factor in Operable Breast Cancer: Results of ABCSG-14

1 reference

12 December 2020

1 reference

12 December 2020

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype

1 reference

12 December 2020

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study

1 reference

12 December 2020

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

1 reference

12 December 2020